Investors

News Release

<< Back
Codexis Reports Second Quarter 2011 Results
Introduces CodeXol(TM) Detergent Alcohols

REDWOOD CITY, Calif., July 28, 2011 /PRNewswire via COMTEX/ --

Codexis, Inc. (Nasdaq: CDXS) today announced introduction of the CodeXol(TM) detergent alcohol product line, and announced financial results for the second quarter ended June 30, 2011.

CodeXol(TM) Detergent Alcohols:

Detergent alcohols - a $6 billion worldwide market - are used to make surfactants which act as cleaning and emulsifying agents in household products. They are widely used in laundry detergents, shampoos and other consumer products. Detergent alcohols today are made from non-sustainable palm kernel and petroleum sources. CodeXol(TM) detergent alcohols will be produced from sustainable sources.

"We look forward to introducing the CodeXol(TM) line of detergent alcohols to the household and consumer products markets," said Alan Shaw, Ph.D., President and Chief Executive Officer. "Major consumer products companies are actively seeking more sustainable raw materials for their products in order to reduce environmental impact and minimize volatility in their supply chains. Detergent alcohols can be made from sugar and, ultimately, sustainable cellulosic biomass. Our proprietary cellulase enzymes, along with the detergent alcohols collaboration with Chemtex that we also announced today, represent important steps toward addressing this growing market need."

The CodeXol(TM) product line, a family of detergent alcohols that is under development, is enabled by Codexis' proprietary CodeEvolver(TM) directed evolution technology.

Second Quarter Financial Highlights:

Revenue: For the second quarter of 2011, the company reported revenues of $26.1 million, an increase of 6% from $24.5 million in the second quarter of 2010. Product revenue of $8.4 million decreased 1% over the same time period primarily due to the timing of product orders. Collaborative R&D revenue of $2.5 million increased 198% from $0.9 million in the second quarter of 2010, driven mainly by funded research for our carbon capture program.

Operating Expenses: Research and development expenses in the second quarter of 2011 were $15.0 million, compared to $13.0 million for the second quarter of 2010. The increase was primarily due to an increase in amortization related to intellectual property purchased from Maxygen, Inc. and stock compensation expenses. Selling, general and administrative expenses in the second quarter of 2011 increased to $9.3 million compared to $8.7 million over the same period of 2010, driven by higher stock compensation expense and higher compensation expense due to headcount increases.

Net Loss: Net loss was ($5.0) million, or ($0.14) per share, based on 35.7 million weighted average common shares outstanding in the second quarter of 2011. This compares to a net loss of ($3.9) million or ($0.15) per share during the second quarter of 2010.

Adjusted EBITDA: On a non-GAAP basis, Adjusted EBITDA decreased from $0.5 million in the second quarter of 2010 to $67,000 in 2011. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation. A reconciliation of net loss to Adjusted EBITDA is presented below.

Cash: Cash, cash equivalents and marketable securities at June 30, 2011, decreased to $72.4 million compared to $82.0 million at March 31, 2011. The company used ($0.3) million in cash from operations in the second quarter.

Outlook

Codexis' statements with regard to its outlook are based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below.

For the full year 2011, Codexis reaffirms its prior guidance and forecasts revenues of $120 million or greater, which would represent growth of 12% or greater compared to 2010. Codexis expects 2011 Adjusted EBITDA will be $5 million or greater.

Recent Developments

  • Codexis announced today a broad collaboration with Chemtex, a wholly-owned company of Italy's Gruppo Mossi & Ghisolfi ("M&G Group"), to develop and produce sustainable detergent alcohols for use in the household products market. The collaboration includes development of second generation detergent alcohols from cellulosic (non-food) biomass. The collaboration combines Chemtex's efficient pretreatment technology with Codexis' high performance enzymes and fermentation process to convert a wide variety of feedstocks into detergent alcohols. The parties expect that the production process will initially be piloted at Chemtex's R&D facility in Rivalta, Italy. Larger scale demonstrations are anticipated at Chemtex's 40,000 metric ton per year cellulosic ethanol plant in Crescentino, Italy that is expected to be operational in 2012. Chemtex will provide engineering services for the design and construction of Codexis commercial facilities for the production of detergent alcohols. Codexis will market products resulting from the collaboration.
  • Codexis announced today that Pedro I. Mizutani, Executive Vice President in charge of upstream business at Raizen Energia Participacoes S.A., had been elected to the Codexis Board of Directors effective July 15, 2011. Mr. Mizutani serves as the Board representative of Raizen, a biofuels joint venture between Shell and Cosan and Codexis' largest stockholder. Raizen is Brazil's largest sugar and ethanol producer. Prior to joining Raizen, Mr. Mizutani served as CEO of Cosan Sugar and Ethanol. On June 2, Codexis announced that Equilon Enterprises LLC, a wholly owned subsidiary of Royal Dutch Shell plc, had completed the transfer of approximately 5.6 million shares of Codexis common stock to Raizen. This transfer occurred as part of the closing of the joint venture.
  • Codexis announced on July 12, 2011 that it had successfully completed a 20,000 liter scale up of the company's proprietary cellulase enzymes. This scale up is an important milestone for Codexis as it continues to move toward commercializing these enzymes. Codexis' cellulase enzymes may be used to convert non-food biomass to fermentable sugars, and ultimately to sustainable products including biofuels and bio-based performance ingredients in household goods such as laundry detergents and shampoos.
  • Codexis and Shell have a research and development collaboration agreement that is focused on the development of advanced biofuels. Consistent with its increasing focus on cellulosic ethanol, Shell has decided to shift resources out of the diesel fuel program and into the cellulosic ethanol program. As part of this resource re-allocation, Shell will reduce the number of funded Codexis full-time equivalents, or FTEs, from 128 to 116 effective mid-August 2011, at which point 8 additional FTEs will move to the cellulosic ethanol program funded by Shell.

Conference Call

Codexis will hold a conference call for investors on July 28, 2011 at 1:30 p.m. PT (4:30 p.m. ET). The conference call dial-in numbers are US: 866-788-0541 or International: 857-350-1679, access code 54501345. A live webcast of the call will also be available from the Investor Relations section of www.codexis.com. A recording of the call will be available by calling US: 888-286-8010 or International: 617-801-6888, access code 93136720 beginning approximately two hours after the call, and will be available for up to thirty days. A webcast replay from today's call will also be available from the Investor Relations section of www.codexis.com approximately two hours after the call and will be available for up to thirty days.

About Codexis, Inc.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell, carbon capture and biobased chemicals. Wastewater treatment is a potential future market.

Forward-Looking Statements

This press release contains forward-looking statements relating to the company's ability to develop and commercialize its CodeXol(TM) line of detergent alcohols, the company's forecast for 2011 revenue and Adjusted EBITDA, the ability of Codexis and Chemtex to develop and commercialize detergent alcohols from a wide variety of feedstocks, the company's ability to develop and produce cellulase enzymes at commercial scale, and funding and staffing on our Shell biofuels research collaboration. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2011, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Codexis, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In Thousands, Except Per Share Amounts)


















Three Months Ended




Six Months Ended






June 30,




June 30,






2011


2010


% change


2011


2010


% change


Revenues:














Product


$ 8,397


$ 8,484


-1%


$ 21,329


$ 14,760


45%


Related party collaborative research and development


14,847


14,653


1%


29,670


30,695


-3%


Collaborative research and development


2,538


851


198%


5,201


1,511


244%


Government grants


273


492


-45%


889


3,214


-72%
















Total revenues


26,055


24,480


6%


57,089


50,180


14%
















Costs and operating expenses:














Cost of product revenues


7,106


6,075


17%


18,756


11,293


66%


Gross margin $


1,291


2,409




2,573


3,467




Gross margin %


15%


28%




12%


23%
































Research and development


14,965


13,004


15%


28,715


25,986


11%


Selling, general and administrative


9,276


8,652


7%


18,289


17,252


6%
















Total costs and operating expenses


31,347


27,731


13%


65,760


54,531


21%
















Loss from operations


(5,292)


(3,251)


63%


(8,671)


(4,351)


99%
















Interest income


71


46


54%


120


74


62%


Interest expense and other, net


16


(654)


nm


34


(1,012)


nm


Loss before provision (benefit) for income taxes


(5,205)


(3,859)


35%


(8,517)


(5,289)


61%


Provision (benefit) for income taxes


(165)


87


nm


(6)


26


nm


Net loss


$ (5,040)


$ (3,946)


28%


$ (8,511)


$ (5,315)


60%
















Net loss per share of common stock,














basic and diluted


$ (0.14)


$ (0.15)




$ (0.24)


$ (0.36)


















Weighted average common shares used in computing net loss per share of common stock, basic and diluted


35,685


26,557




35,402


14,701




Codexis, Inc.


Condensed Consolidated Balance Sheets


(Unaudited)


(In Thousands)











June 30,



December 31,




2011



2010


Assets







Current assets:







Cash and cash equivalents


$ 32,082



$ 72,396


Marketable securities


14,593



-


Accounts receivable, net


11,306



10,620


Related party accounts receivable


-



4,713


Inventories


4,187



2,817


Prepaid expenses and other current assets


2,380



1,646


Total current assets


64,548



92,192









Restricted cash


1,512



1,466


Non-current marketable securities


25,769



1,650


Property and equipment, net


21,611



21,452


Intangible assets, net


18,301



20,158


Goodwill


3,241



3,241


Other non-current assets


1,153



1,141


Total assets


$ 136,135



$ 141,300









Liabilities and stockholders' equity







Current liabilities:







Accounts payable


$ 7,714



$ 9,208


Accrued compensation


5,019



8,107


Other accrued liabilities


7,406



5,630


Deferred revenues


386



455


Related party deferred revenues


4,084



4,084


Total current liabilities


24,609



27,484









Deferred revenues, net of current portion


1,579



1,671


Related party deferred revenues, net of current portion


1,361



3,403


Other long-term liabilities


1,800



1,381


Total liabilities


29,349



33,939









Stockholders' equity:







Common stock


4



4


Additional paid-in capital


283,028



275,540


Accumulated other comprehensive loss


415



(34)


Accumulated deficit


(176,661)



(168,149)


Total stockholders' equity


106,786



107,361


Total liabilities, and stockholders' equity


$ 136,135



$ 141,300

Codexis, Inc.

Condensed Consolidated Statements of Cash Flow

(Unaudited)

(In Thousands)








Six Months Ended



June 30,



2011


2010

Operating activities:





Net loss


$ (8,511)


$ (5,315)

Adjustments to reconcile net loss to net cash used in operating activities:





Amortization of intangible assets


1,858


302

Depreciation and amortization of property and equipment


3,760


3,438

Revaluation of redeemable convertible preferred stock warrant liability


-


677

Loss (gain) on disposal of property and equipment


59


-

Gain from extinguishment of asset retirement obligation


(124)


-

Stock-based compensation


4,856


3,951

Accretion of asset retirement obligation


29


-

Amortization of debt discount


-


104

Accretion (amortization) of premium/discount on marketable securities


51


183

Changes in operating assets and liabilities:





Accounts receivable


4,027


(42)

Inventories


(1,370)


739

Prepaid expenses and other current assets


(735)


(3,126)

Other assets


(13)


2,395

Accounts payable


(1,493)


(1,413)

Accrued compensation


(3,088)


(1,477)

Related party payable


-


(1,046)

Other accrued liabilities


2,554


(5,133)

Deferred revenues


(2,203)


(12,950)

Net cash provided by (used in) operating activities


(343)


(18,713)






Investing activities:





(Increase) decrease in restricted cash


(46)


65

Purchase of property and equipment


(4,187)


(3,192)

Purchase of marketable securities


(38,152)


(49,051)

Proceeds from sale of marketable securities


-


1,605

Proceeds from maturities of marketable securities


-


21,960

Net cash provided by (used in) investing activities


(42,385)


(28,613)






Financing activities:





Principal payments on financing obligations


-


(2,681)

Payments in preparation for initial public offering


-


(3,106)

Proceeds from issuance of common stock on IPO, net of underwriting discounts


-


72,539

Proceeds from exercises of stock options


2,390


254

Net cash provided by (used in) financing activities


2,390


67,006






Effect of exchange rate changes on cash and cash equivalents


24


(52)






Net increase in cash and cash equivalents


(40,314)


19,628

Cash and cash equivalents:





Beginning of the period


72,396


31,785

End of the period


32,082


51,413






Marketable securities at the end of period


40,362


48,894






Cash, cash equivalents and marketable securities


$ 72,444


$ 100,307






Reconciliation of GAAP to Non-GAAP Financial Information

In this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA to evaluate the effectiveness of our business strategies.

A reconciliation of GAAP net loss to Adjusted EBITDA is included in the table below.

Codexis, Inc.

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(Unaudited)

(In Thousands)



Three Months Ended


Six Months Ended


June 30,


June 30,

Calculation of Adjusted EBITDA

2011


2010


2011


2010

Net loss

$ (5,040)


$ (3,946)


$ (8,511)


$ (5,315)

Adjustments:








Minus: Interest income

(71)


(46)

(120)


(74)

Plus: Interest expense

-


96


-


394

Plus: Income taxes

(165)


87


(6)


26

Plus: Depreciation and amortization

2,794


1,884


5,618


3,740

Plus: Stock-based compensation

2,549


2,171


4,835


3,885

Plus: Preferred stock warrant fair market valuation adjustment

-


281


-


677









Adjusted EBITDA

$ 67


$ 527


$ 1,816


$ 3,333

Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:

  • Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
  • Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
  • Non-cash compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.

Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.

Contacts:

Investors: Henk Adriaenssens, ir@codexis.com, 650-421-8331
Media: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.

SOURCE Codexis, Inc.

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contacts | Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSISTM

We are an industrial biotechnology company delivering real business results through biobased innovation in chemicals, fuels, pharmaceuticals, consumer, and industrial products.

PHARMACEUTICAL ENZYMES


Supporting faster, cleaner, more efficient pharmaceutical manufacturing processes

Codexis delivers a range of chemicals at kilogram to multi-ton scale, through a partnered manufacturing network

CODEXIS

WHAT WE DO


Codexis delivers revolutionary biocatalytic routes that no one else can


CODEXIS

MEDIA CENTER


Visit our Media Center for the latest product information, videos, imagery, technical papers and press information.


CAREERS AT CODEXIS

An opportunity to make a difference.

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information
for the investment community

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue